Vancomycin (Vancomycin HCl In 5 % Dextrose) Patent Expiration, LOE Window & CMS Spending

Vancomycin (Vancomycin HCl In 5 % Dextrose) by Baxter Healthca: FDA Orange Book LOE 2035-11-06, 3 AB generics, $61K 2024 CMS Part D & Medicaid spend, and $428 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBaxter Healthca
FDA Application & PathwayN213895 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-11-06
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$61K
2024 Medicare Part D Spend$25K
2024 Medicaid Spend$37K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($428 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.